ACU vs SKIN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ACU presents a dichotomy between a rock-solid balance sheet and deteriorating short-term operational momentum. The Piotroski F-Score of 4/9 indicates stable but mediocre financial health, while the absence of an Altman Z-Score is offset by an exceptionally low Debt/Equity ratio (0.24) and a high Current Ratio (4.21). While the stock is fairly valued—trading between its Graham Number ($40.16) and Intrinsic Value ($48.95)—the recent Q/Q EPS collapse of -47.8% and a bearish technical trend (0/100) suggest significant near-term headwinds.
The Beauty Health Company (SKIN) presents a high-risk profile characterized by a stable Piotroski F-Score of 5/9 but severely compromised financial health. While valuation metrics like Price/Sales (0.39) and Forward P/E (8.30) appear attractive, they are overshadowed by an extreme Debt/Equity ratio of 6.20 and negative revenue growth. The stock is in a severe long-term downtrend, losing over 90% of its value over 3 and 5 years, suggesting the market is pricing in significant solvency or growth risks.
Compare Another Pair
Related Comparisons
ACU vs SKIN: Head-to-Head Comparison
This page compares Acme United Corporation (ACU) and The Beauty Health Company (SKIN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.